Peptide Research Database
Search, filter by category, and compare key research attributes.
Fat Loss • Small Molecule / Metabolic • Experimental
Small-molecule NNMT inhibitor marketed as 5-Amino-1MQ for metabolic research; supports NAD+ elevation and fat oxidation.
Mechanism: Inhibits NNMT to elevate NAD+, enhance fat oxidation, imp…
Half-life: 3.8-6.9 hours
MW: 286.11 g/mol
FDA-approved
Increased bone mineral density • Reduced vertebral and nonvertebral fractures
Mechanism: Agonist at PTH receptor type 1, activates cAMP signaling,…
Half-life: ~1–1.7 hours
MW: 3961.6 g/mol
Cosmetic active / Research-only
Reduces expression wrinkles • Improves skin texture
Mechanism: Mimics SNAP-25, inhibits SNARE complex formation, reduces…
Half-life: Topical; systemic PK not established
MW: —
Cosmetic active / Research-only
Up to 38% wrinkle reduction • Relaxes facial muscles
Mechanism: Extended SNAP-25 mimetic, inhibits neurotransmitter relea…
Half-life: Topical; systemic PK not established
MW: ≈1075.2 g/mol
Cognitive • Synthetic Peptide / Nootropic Research • Experimental
Adamax is a synthetic adamantane modified Semax analog researched for neurotrophic signaling, cognitive pathway modulation, and improved peptide stability compared with standard Semax.
Mechanism: Proposed to act as a modified Semax analog with enhanced …
Half-life: Not established; designed for improved stability compared with Semax
MW: ≈1033 g/mol
FDA-approved
Increases pain-free sun exposure in EPP • Reduces phototoxic reactions
Mechanism: Binds MC1-R, increases eumelanin production, provides pho…
Half-life: ~30 minutes (plasma); ~15 h (from implant)
MW: 1646.9 g/mol
Research-only
Cardioprotection • Anti-hypertension
Mechanism: Activates ACE2/Ang1-7/Mas axis, vasodilation, anti-fibros…
Half-life: Short; orally active analog tested in rodents
MW: 902.0 g/mol
Fat Loss • Performance / Research-only • Experimental
Synthetic GH fragment promoting lipolysis; GRAS status but unapproved for therapy.
Mechanism: Selective lipolysis stimulation without IGF-1/glucose imp…
Half-life: ~20-30 minutes
MW: 1815.1 g/mol
Fat Loss • Synthetic Peptide / Tissue Protective (Investigational)
ARA 290, also known as cibinetide, is an 11 amino acid peptide derived from erythropoietin helix B that selectively activates the innate repair receptor to promote anti inflammatory and tissue protective signaling without erythropoietic stimulation.
Mechanism: Selective agonist of the innate repair receptor complex; …
Half-life: Short plasma half life (reported minutes; tissue protective signaling persists longer in models)
MW: ≈1257 g/mol
Research-only
Reduces fibrosis • Cardioprotection
Mechanism: RXFP1 agonist, activates ERK1/2, upregulates MMPs, anti-f…
Half-life: Short; stabilized vs native relaxin-2
MW: ≈5000 g/mol
Fat Loss • Small Molecule / Metabolic (Mitochondrial Uncoupler) • Experimental
BAM15 is a synthetic small-molecule mitochondrial protonophore uncoupler used as a research tool to uncouple oxidative phosphorylation and increase mitochondrial respiration without reported plasma membrane depolarization in referenced studies.
Mechanism: Acts as a protonophore to uncouple oxidative phosphorylat…
Half-life: Not established (limited public PK; primarily preclinical/in vitro characterization)
MW: 340.29 g/mol
Cognitive • Cognitive Enhancement / Neurotrophic Peptide • Experimental
CNTF analog for BDNF research in cognition.
Mechanism: BDNF upregulation, LTP enhancement.
Half-life: 1–2 hours
MW: ~1,800 g/mol
FDA-approved
Anticoagulation during PCI • Alternative for HIT
Mechanism: Binds catalytic site and exosite of thrombin, inhibits cl…
Half-life: ~25 minutes (normal renal function)
MW: 2180.3 g/mol
Experimental • Healing / Regenerative • Experimental
Regenerative peptide for tissue repair and inflammation; banned in sports.
Mechanism: Promotes angiogenesis, collagen synthesis, and mucosal re…
Half-life: ~30 minutes to 4 hours
MW: 1419.5 g/mol
FDA-approved
Increased sexual desire in premenopausal women with HSDD • Improved sexual satisfaction
Mechanism: Bremelanotide (PT-141) is a synthetic melanocortin recept…
Half-life: ~2.7 hours
MW: 1025.2 g/mol
Bioregulator / Research-only
Lung tissue support • Anti-degeneration
Mechanism: Chromatin remodeling, gene regulation in bronchial cells.
Half-life: Not established (small tripeptide)
MW: 391.39 g/mol
Fat Loss • Weight Loss / Metabolic
Long-acting amylin agonist for weight loss; in Phase 3 trials.
Mechanism: Amylin agonism for satiety, gastric delay.
Half-life: ~6–7 days
MW: ~4749 g/mol
Experimental • Short Peptide Bioregulator (Research) • Experimental
Cardiogen is a short peptide bioregulator complex studied in cardiac tissue research for potential gene expression modulation and myocardial cellular support.
Mechanism: Proposed to modulate gene expression in cardiac tissue ce…
Half-life: Not established (limited PK data; primarily research context)
MW: Low molecular weight peptide fraction
Experimental • Bioregulator / Research-only • Experimental
Cartilage bioregulator for joint longevity; Russian research.
Mechanism: Modulates fibroblast gene expression, inhibits MMP-9.
Half-life: Short (hours)
MW: 317.3 g/mol
Experimental • Neurotrophic Peptide Complex • Experimental
Neuroprotection • Cognitive recovery
Mechanism: Mimics neurotrophic factors, neuroprotection, regeneratio…
Bioregulator / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not established
MW: 408.47 g/mol
Muscle/Recovery • Growth Hormone Releasing • Experimental
Increased GH release • Improved sleep
Mechanism: Stimulates pituitary GH release via cAMP pathway.
Half-life: ~8 hours
MW: 3367.8 g/mol
Research-only
Pulsatile GH release • Muscle growth
Mechanism: Stimulates pituitary GH release via cAMP, short-acting pu…
Half-life: Short (hours) vs DAC variant
MW: ≈3368 g/mol
Muscle/Recovery • Performance / Recovery • Experimental
Synergistic GHRH/GHRP blend for pulsatile GH.
Mechanism: Synergistic GH stimulation.
Half-life: CJC: ~30 min; Ipa: ~2 hours
MW: Varies
Compounding / Research-only
Sustained GH elevation • Anti-aging
Mechanism: Stimulates pituitary GH release via cAMP, extended by DAC.
Half-life: ~6–8 days (albumin binding via DAC; human studies)
MW: ≈3647 g/mol
Cognitive • Neuro / Nootropic (peptide complex) • Experimental
Neurological recovery • Anti-inflammatory
Mechanism: Neuroprotection, anti-inflammation, neurotrophic effects.
Clinical trial
Weight loss • Glycemic control
Mechanism: Dual agonism for glucose control and weight loss.
Half-life: ~13 hours (sc) in human PK models
MW: —
Bioregulator / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not established
MW: 393.39 g/mol
Muscle/Recovery • Sleep / Research-only • Experimental
Neuropeptide for sleep induction and stress modulation.
Mechanism: Promotes delta sleep, suppresses cortisol.
Half-life: ~7-15 minutes
MW: 848.81 g/mol
Cognitive • Small Molecule / Neuro • Experimental
Angiotensin-IV–derived peptidomimetic studied preclinically for synaptogenic/neurotrophic signaling (research-only).
Mechanism: Putative HGF/c-Met pathway modulator; investigated for co…
MW: 504.70 g/mol
Cosmetic active / Research-only
Wrinkle reduction • Skin smoothing
Mechanism: Blocks acetylcholine receptors, reduces muscle contraction.
Half-life: Topical; systemic PK not established
MW: —
Experimental • Clinical trial / Longevity research
Mitochondria-targeted tetrapeptide (SS-31) investigated for mitochondrial dysfunction conditions.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~4–5 h (iv) in human studies
MW: 627.8 g/mol
FDA-approved
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~3.8 hours (sc)
MW: 4491.4 g/mol
Longevity • Anti-Aging / Research-only • Experimental
Pineal tetrapeptide for telomere and melatonin research.
Mechanism: Telomerase activation, melatonin regulation.
Half-life: Short (~10 min)
MW: 390.35 g/mol
Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Varies; protein biologic
MW: ≈38–40 kDa (glycosylation dependent)
Longevity / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Experimental; not established
MW: —
Performance / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Short (minutes–hours; animal PK)
MW: ≈1729 g/mol
Cosmetic • Regenerative / Skin-Hair
Associated with collagen/elastin synthesis, angiogenesis, antioxidant actions.
Mechanism: Associated with collagen/elastin synthesis, angiogenesis,…
MW: 403.92 g/mol
Compounding / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Short; both ~1–2 h combined activity
MW: Mixture
Growth Hormone Releasing
GH release • Increased appetite
Mechanism: Stimulates GH release and increases appetite.
Half-life: ~30 minutes
MW: 873.0 g/mol
Muscle/Recovery • Regenerative-Cosmetic Blend • Experimental
Blend for cosmetic and regenerative research.
Mechanism: Collagen, inflammation, repair synergy.
Half-life: Varies by component
MW: Varies
Cosmetic • Endogenous Tripeptide / Antioxidant
Endogenous tripeptide antioxidant (GSH) central to cellular redox balance and detoxification; widely researched for oxidative stress and liver support.
Mechanism: Acts as primary intracellular antioxidant; neutralizes RO…
Half-life: ~1.5 hours (IV); oral bioavailability limited
MW: 307.32 g/mol
Compounding / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~56–76 minutes (human PK studies)
MW: ≈887.0 g/mol
Endogenous Glycoprotein Hormone / FDA-approved prescription biologic (indication-specific)
Human chorionic gonadotropin is a placental glycoprotein hormone and prescription biologic that acts as an LH receptor agonist, used in indication-specific fertility and gonadal function protocols.
Mechanism: Acts as an LH receptor agonist to stimulate testicular te…
Half-life: ~24-36 hours biological half life (route and product dependent)
MW: Variable glycoprotein; approximately 36.7 to 38 kDa depending on glycosylation/source
FDA-approved prescription biologic (indication-specific)
Somatropin (rhGH) is a 191-amino-acid recombinant human growth hormone used as an FDA-approved prescription biologic for specific pediatric and adult indications; activates GHR → IGF-1 axis to drive growth and metabolic effects.
Mechanism: Agonist at GHR → activates JAK/STAT signaling and downstr…
Half-life: ~3 hours (SC/IM absorption-limited; serum decline ~3–5 hours)
MW: 22124 g/mol
Fat Loss • Longevity / Research-only • Experimental
MDP for cellular defense and anti-aging.
Mechanism: Anti-apoptotic, mitochondrial stabilization.
Half-life: ~2-4 hours
MW: 2687.3 g/mol
Hormone Axis (Growth / Metabolic)
Neuroprotective signaling • Tissue repair
Mechanism: Endogenous hormone mediating GH effects; neuroprotective …
Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Longer than native IGF-1 in vitro; human PK not established in labels
MW: Reported ≈9.1 kDa (supplier-dependent)
Muscle/Recovery • Growth Hormone Releasing • Experimental
GH release • Improved sleep quality
Mechanism: Selective GH secretagogue with minimal side effects.
Half-life: ~2 hours
MW: 711.9 g/mol
Experimental • HPG Axis / Research-only • Experimental
HPG axis stimulator for hormone research.
Mechanism: GnRH stimulation for LH/FSH release.
Half-life: ~4 minutes
MW: 1302.5 g/mol
Clinical research / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Short; study-dependent
MW: ≈5857 g/mol
Muscle/Recovery • Regenerative Blend • Experimental
Blend for regeneration research.
Mechanism: Inflammation, repair, angiogenesis synergy.
Half-life: Varies
MW: Varies
Experimental • Anti-Inflammatory / Gut-Joint • Experimental
Tripeptide motif from α-MSH (11–13) used in research on inflammatory signaling and barrier biology.
Mechanism: Alpha-MSH tripeptide fragment associated with anti-inflam…
MW: 342.44 g/mol
FDA-approved
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~3 hours (immediate-release); depot provides sustained levels
MW: 1209.4 g/mol (free base); 1269.4 g/mol (acetate)
Experimental • Antimicrobial / Research-only • Experimental
Antimicrobial peptide for infection and healing research.
Mechanism: Membrane disruption, immune modulation.
Half-life: ~1-2 hours
MW: 4493.3 g/mol
Clinical trial
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Long (monthly or less frequent dosing in trials)
MW: ≈145–154 kDa (conjugate; assay-dependent)
Cosmetic • Skin / Research-only
α-MSH analog for tanning research.
Mechanism: Melanogenesis stimulation, photoprotection.
Half-life: ~30 minutes
MW: 1646.85 g/mol
Cosmetic • Cosmetic / Tanning • Experimental
Tanning • Appetite suppression
Mechanism: Activates melanocortin receptors to stimulate melanin pro…
Half-life: ~36 hours
MW: 1024.2 g/mol
Fat Loss • Metabolic / Research-only • Experimental
MDP for metabolic and anti-aging research.
Mechanism: AMPK activation, metabolic regulation.
Half-life: ~2-4 hours
MW: 2174.6 g/mol
Fat Loss • Coenzyme
NAD+ is a critical cellular coenzyme involved in energy production, DNA repair, and metabolic regulation. Levels decline with age, and supplementation is commonly used to support mitochondrial health, cognitive function, and overall vitality.
Half-life: Minutes to hours (rapidly metabolized)
MW: 663.43 g/mol
FDA-approved
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~1.7 hours (sc); depot has prolonged release
MW: 1019.3 g/mol
Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Unknown (preclinical)
MW: ≈2292 g/mol
Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Very short; rapidly degraded by peptidases
MW: ≈4534 g/mol
Cosmetic active / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Topical; systemic PK not established
MW: ≈802.07 g/mol
Cosmetic active / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Topical; systemic PK not established
MW: ≈694.9 g/mol
Cosmetic active / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Topical; systemic PK not established
MW: ≈578.8 g/mol
Cosmetic active / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Topical; systemic PK not established
MW: —
Performance / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Extended vs native MGF; no validated human PK
MW: ≈8–10 kDa (PEG dependent)
Clinical trial
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~110 hours (EuPort™ albumin-binding domain; weekly dosing)
MW: ≈4094 g/mol
Clinical trial
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Long-acting (once-weekly; precise human t½ not yet widely published)
MW: —
Bioregulator / Research-only
Synthetic tripeptide (EDR) used in Russian 'bioregulator' research literature; not FDA-approved.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not established in humans
MW: 450.41 g/mol
Compounding / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Reported short; human diagnostic use in Japan
MW: 801.98 g/mol
Experimental • Libido / Sexual Function • Experimental
Libido enhancement • Sexual function
Mechanism: Activates melanocortin receptors to enhance libido.
Half-life: ~2 hours
MW: 1025.3 g/mol
Compounding / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Topical kinetics not published; peptide absorption limited
MW: 1025.2 g/mol
Compounding / Rx in some countries
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: ~1 h (sc); same as Forteo reference
MW: ≈4118 g/mol
Clinical trial
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not firmly established in public sources; studied as short-acting sc peptide
MW: 790.97 g/mol
Fat Loss • Weight Loss / Metabolic
Triple receptor agonist for obesity research.
Mechanism: Appetite suppression, energy expenditure increase.
Half-life: ~120 hours (~5 days)
MW: 4845.4 g/mol
Cognitive • Compounding / Research-only • Experimental
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not established (varies by route; nasal studied in RU)
MW: ≈751.9 g/mol
Fat Loss • FDA-approved • Established
Significant weight loss (up to 15% body weight) • Improved glycemic control in type 2 diabetes
Mechanism: Semaglutide is a GLP-1 receptor agonist that mimics the a…
Half-life: ~7 days
MW: 4113.58 g/mol
GLP-1/Metabolic • Weight-Loss / Metabolic
Incretin-based therapies improving satiety and glycemic control; tirzepatide also activates GIP.
Mechanism: Incretin-based therapies improving satiety and glycemic c…
Experimental • Nootropic / Research-only • Experimental
Nootropic for cognitive research.
Mechanism: BDNF upregulation, neuroplasticity.
Half-life: ~20-30 minutes (nasal)
MW: 813.92 g/mol
Muscle/Recovery • Growth Hormone Releasing • Experimental
GHRH analog for GH research.
Mechanism: Stimulates pulsatile GH release.
Half-life: ~11-12 minutes
MW: 3357.96 g/mol
FDA-approved
Significant weight loss in genetic obesity disorders • Reduced hunger
Mechanism: Setmelanotide is a melanocortin-4 receptor (MC4R) agonist…
Half-life: ~11 hours
MW: 1117.3 g/mol
Cosmetic active (biotech) / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Topical; systemic PK not applicable
MW: ≈6.2 kDa (protein growth factor)
Fat Loss • Metabolic / Research-only • Experimental
Pan-ERR agonist exercise mimetic.
Mechanism: Pan-ERR agonism for metabolic reprogramming.
Half-life: Not established
MW: 467.5 g/mol
Mitochondrial / Investigational
Mitochondrial protector for energy and anti-aging research.
Mechanism: Mitochondrial membrane stabilization, ROS reduction.
Half-life: ~1-2 hours
MW: 639.8 g/mol
Bioregulator / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not established (small tripeptide)
MW: 391.39 g/mol
Clinical trial
Weight loss • Improved liver fibrosis
Mechanism: Dual agonism for metabolic control, weight loss, fibrosis…
Half-life: ~6 days (once-weekly)
MW: ≈4232 g/mol
Muscle/Recovery • Healing / Mobility • Experimental
Associated with actin modulation, cell migration, fibrosis modulation.
Mechanism: Associated with actin modulation, cell migration, fibrosi…
FDA-approved
Increased bone mineral density • Reduced vertebral and nonvertebral fractures
Mechanism: Teriparatide is a synthetic form of parathyroid hormone (…
Half-life: ~1 hour (sc)
MW: 4117.8 g/mol
Fat Loss • GH Secretagogue / Fat Loss • Established
GHRH analog for VAT research.
Mechanism: Stimulates pulsatile GH for VAT reduction.
Half-life: 26-38 minutes
MW: 5135.9 g/mol
Experimental • Short Peptide Bioregulator (Endocrine Research) • Experimental
Testagen is a short tetrapeptide bioregulator commonly referenced as KEDG and used in research contexts exploring endocrine related cellular regulation and signaling.
Mechanism: Proposed to influence cellular regulatory signaling and g…
Half-life: Not established (limited public PK data; primarily research context)
MW: 447.44 g/mol
Bioregulator / Research-only
Therapeutic benefits not fully established.
Mechanism: Mechanism of action not fully established in publicly ava…
Half-life: Not established
MW: 319.27 g/mol
Longevity • Bioregulator / Extractive • Experimental
Immune restoration • Anti-aging
Mechanism: Stimulates T cell differentiation, gene regulation.
Half-life: Not established (polypeptide complex)
MW: Mixture
Bioregulator / Research-only
Immune normalization • Anti-aging
Mechanism: Stimulates T cell differentiation, immunomodulation.
Half-life: Not firmly established (small dipeptide)
MW: 333.34 g/mol
Experimental • Immune Modulation • Experimental
Immune modulation (research)
Mechanism: Thymic peptide complex historically explored for immune m…
Immune / Research-only
Thymic immunomodulator for infection research.
Mechanism: Immune modulation, cytokine balance.
Half-life: ~2 hours
MW: 3108.3 g/mol
Experimental • Immune / Inflammation • Experimental
Inflammation modulation • Immune support
Mechanism: Actin modulation, immune support.
Research-only
Tissue repair • Anti-fibrosis
Mechanism: Sequesters G-actin, modulates cytoskeleton, anti-fibrotic.
Half-life: Not well established in humans
MW: ≈4963 g/mol
Fat Loss • FDA-approved • Established
Superior weight loss compared to semaglutide (up to 22.5% body weight) • Excellent glycemic control in type 2 diabetes
Mechanism: Tirzepatide is a dual GIP (glucose-dependent insulinotrop…
Half-life: ~5 days
MW: ≈4813 g/mol
Experimental • Endogenous Neuropeptide / Research • Experimental
VIP is an endogenous 28 amino acid neuropeptide that activates VPAC receptors to increase cAMP, driving vasodilation, bronchodilation, smooth muscle relaxation, and immunomodulatory signaling in experimental models.
Mechanism: VIP activates VPAC receptors to increase intracellular cA…
Half-life: Not established (rapid enzymatic degradation; route dependent)
MW: 3325.8 g/mol
Bioregulator / Research-only
Khavinson-style vascular 'bioregulator' sold as peptide complex A-3 (mixture), not a single defined peptide.
Mechanism: Normalizes vascular metabolism.
Half-life: Not established in humans
MW: 405.36 g/mol
Experimental • Short Peptide Bioregulator (Vascular Research) • Experimental
Vesugen is a short vascular bioregulator peptide commonly referenced as KED (Lys Glu Asp) and used in research contexts exploring endothelial signaling, vessel function, and circulatory markers.
Mechanism: Proposed to modulate gene expression and cellular signali…
Half-life: Not established (limited public PK data; primarily research context)
MW: ≈390.4 g/mol
Bioregulator / Research-only
Anti-aging • Immune support
Mechanism: Chromatin decondensation, gene activation, immune modulat…
Half-life: Not established in humans
MW: 275.30 g/mol